| Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity E Volz, V Hill, JT McCrone, A Price, D Jorgensen, Á O’Toole, J Southgate, ... Cell 184 (1), 64-75. e11, 2021 | 1059 | 2021 |
| Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study KA Twohig, T Nyberg, A Zaidi, S Thelwall, MA Sinnathamby, S Aliabadi, ... The Lancet Infectious Diseases 22 (1), 35-42, 2022 | 801 | 2022 |
| Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7 B Meng, SA Kemp, G Papa, R Datir, IATM Ferreira, S Marelli, WT Harvey, ... Cell reports 35 (13), 2021 | 424 | 2021 |
| Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B. 1.1. 7: an ecological study MS Graham, CH Sudre, A May, M Antonelli, B Murray, T Varsavsky, ... The Lancet Public Health 6 (5), e335-e345, 2021 | 337 | 2021 |
| Sexually transmitted hepatitis C infection: the new epidemic in MSM? D Bradshaw, G Matthews, M Danta Current opinion in infectious diseases 26 (1), 66-72, 2013 | 183 | 2013 |
| Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant P Elliott, D Haw, H Wang, O Eales, CE Walters, KEC Ainslie, C Atchison, ... Science 374 (6574), eabl9551, 2021 | 115 | 2021 |
| A comparison of seminal hepatitis C virus (HCV) RNA levels during recent and chronic HCV infection in HIV-infected and HIV-uninfected individuals D Bradshaw, F Lamoury, B Catlett, TL Applegate, J Mcallister, GJ Dore, ... The Journal of infectious diseases 211 (5), 736-743, 2015 | 48 | 2015 |
| Direct ex vivo evaluation of long-lived protective antiviral memory B cell responses against hepatitis B virus SM Ward, P Phalora, D Bradshaw, H Leyendeckers, P Klenerman The Journal of infectious diseases 198 (6), 813-817, 2008 | 41 | 2008 |
| Depression, lifestyle factors and cognitive function in people living with HIV and comparable HIV‐negative controls D De Francesco, J Underwood, E Bagkeris, M Boffito, FA Post, ... HIV medicine 20 (4), 274-285, 2019 | 34 | 2019 |
| The clinical application of plasma K aposi sarcoma herpesvirus viral load as a tumour biomarker: results from 704 patients IU Haq, A Dalla Pria, P Papanastasopoulos, K Stegmann, D Bradshaw, ... HIV medicine 17 (1), 56-61, 2016 | 31 | 2016 |
| Interpreting viral deep sequencing data with GLUE JB Singer, EC Thomson, J Hughes, E Aranday-Cortes, J McLauchlan, ... Viruses 11 (4), 323, 2019 | 27 | 2019 |
| Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 infection early in the pandemic and the role of unidentified cases in transmission LB Snell, CL Fisher, U Taj, O Stirrup, B Merrick, A Alcolea-Medina, ... Clinical Microbiology and Infection 28 (1), 93-100, 2022 | 25 | 2022 |
| Screening for HIV-related neurocognitive impairment in clinical practice: challenges and opportunities TJ Barber, D Bradshaw, D Hughes, L Leonidou, A Margetts, D Ratcliffe, ... AIDS care 26 (2), 160-168, 2014 | 25 | 2014 |
| HIV/HCV/HBV testing in the emergency department: a feasibility and seroprevalence study D Bradshaw, C Rae, M Rayment, N Turner, R Turner, G Pickard, K Pillay, ... HIV medicine 19, 52-57, 2018 | 24 | 2018 |
| Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy DA Smith, D Bradshaw, JL Mbisa, CF Manso, DF Bibby, JB Singer, ... Journal of Viral Hepatitis 28 (9), 1256-1264, 2021 | 22 | 2021 |
| Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study AM Geretti, AJ Stockdale, SH Kelly, M Cevik, S Collins, L Waters, G Villa, ... MedRxiv, 2020.08. 07.20170449, 2020 | 22 | 2020 |
| Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase D Bradshaw, S Malik, C Booth, M Van Houtte, T Pattery, A Waters, ... Antimicrobial agents and chemotherapy 51 (12), 4489-4491, 2007 | 21 | 2007 |
| Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group D Bradshaw, JL Mbisa, AM Geretti, BJ Healy, GS Cooke, GR Foster, ... Journal of Infection 79 (6), 503-512, 2019 | 20 | 2019 |
| Transmission of hepatitis C virus in HIV‐positive and PrEP‐using MSM in England D Bradshaw, TI Vasylyeva, C Davis, OG Pybus, J Thézé, EC Thomson, ... Journal of viral hepatitis 27 (7), 721-730, 2020 | 18 | 2020 |
| COVID‐19 mortality among people with diagnosed HIV compared to those without during the first wave of the COVID‐19 pandemic in England AE Brown, SE Croxford, S Nash, J Khawam, P Kirwan, M Kall, ... HIV medicine 23 (1), 90-102, 2022 | 16 | 2022 |
